Takeda’s Zasocitinib Landmark Ph3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment12/18TDnetPDF(321KB)
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in PV12/8TDnetPDF(326KB)
Protagonist Therapeutics社との、真性多血症におけるヘマトクリット値の持続的なコントロールを示したrusfertide長期データの第67回ASH年次総会での発表12/8TDnetPDF(468KB)
Earnings Report (Kessan Tanshin) for the Six-month Period Ended September 30, 2025 (IFRS, Consolidated)10/30TDnetPDF(765KB)
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 20259/8TDnetPDF(7MB)
世界睡眠学会「World Sleep 2025」におけるナルコレプシータイプ1を対象とした画期的なoveporexton(TAK-861)の第3相臨床試験プログラムのデータ発表について9/8TDnetPDF(9MB)
Statement on Inadvertent Abstract Disclosure for Opevorexton (TAK-861) by World Sleep Congress7/31TDnetPDF(244KB)
Earnings Report (Kessan Tanshin) for the Three-month Period Ended June 30, 2025 (IFRS, Consolidated)7/30TDnetPDF(790KB)
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 17/14TDnetPDF(261KB)
Takeda Completes Disposal of Treasury Shares under the LTIP for Company Group Employees Outside of Japan with Partial Forfeiture7/8TDnetPDF(199KB)
Notice Concerning Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan6/10TDnetPDF(254KB)